Analysts Set Stryker Corporation (NYSE:SYK) Target Price at $380.40

Stryker Corporation (NYSE:SYK) has earned an average rating of “Moderate Buy” from the twenty-three ratings firms that are currently covering the firm, Marketbeat reports. Five analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $378.75.

Several research analysts have commented on the company. Wells Fargo & Company cut their target price on Stryker from $418.00 to $348.00 and set an “overweight” rating on the stock in a report on Wednesday, September 9th. BMO Capital Markets reissued an “outperform” rating and set a $317.00 target price on shares of Stryker in a research report on Wednesday, September 9th. Evercore set a $350.00 price target on shares of Stryker in a report on Monday, July 6th. Leerink Partners dropped their price target on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. Finally, Truist Financial upped their price objective on shares of Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a research note on Friday, July 31st.

Stryker Stock Performance

NYSE:SYK opened at $280.36 on Tuesday. The stock’s 50-day simple moving average is $321.03 and its 200 day simple moving average is $323.18. The firm has a market capitalization of $107.54 billion, a PE ratio of 29.05, a price-to-earnings-growth ratio of 1.79 and a beta of 0.76. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker has a twelve month low of $267.00 and a twelve month high of $392.55.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the company earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts anticipate that Stryker will post 15 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.3%. Stryker’s dividend payout ratio is 36.48%.

Insider Buying and Selling

In other Stryker news, insider Debra King sold 826 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider owned 6,102 shares in the company, valued at $2,005,178.22. This represents a 6.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 351,267 shares of company stock valued at $118,197,701 over the last 90 days. Company insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On Stryker

Institutional investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company grew its position in Stryker by 8.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 859,544 shares of the medical technology company’s stock valued at $270,642,000 after purchasing an additional 65,333 shares during the period. Palogic Value Management L.P. grew its holdings in Stryker by 4.3% during the second quarter. Palogic Value Management L.P. now owns 1,313 shares of the medical technology company’s stock worth $413,000 after buying an additional 54 shares in the last quarter. Tidal Investments LLC grew its holdings in Stryker by 174.2% during the second quarter. Tidal Investments LLC now owns 111,457 shares of the medical technology company’s stock worth $35,091,000 after buying an additional 70,805 shares in the last quarter. Van Hulzen Asset Management LLC raised its position in Stryker by 3.3% in the 2nd quarter. Van Hulzen Asset Management LLC now owns 15,148 shares of the medical technology company’s stock valued at $4,769,000 after buying an additional 481 shares during the last quarter. Finally, National Pension Service lifted its stake in Stryker by 2.4% during the 2nd quarter. National Pension Service now owns 721,186 shares of the medical technology company’s stock valued at $227,058,000 after acquiring an additional 16,962 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Company Profile

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker’s principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.